Kornimate/medical-research-clean huggingface dataset:
immune and inflammatory indices in peripheral blood predict prognosis of glioma and correlate with grades and subtypes

Conditions: Glioma; Immune Suppression

Summary: our study considered the relevant immune and inflammatory indices, such as immunoglobulin kappa light chain, tnf, and cd4+ helper t lymphocyte% in a multi-institutional study with a large patient cohort (n=1282) from the east, northeast, and southeast of china. our study shed light on the association of peripheral immune system status with prognosis, tumor grade, and subtype of glioma, which can potentially benefit future diagnostic and prognostic processes of glioma given its noninvasive nature. moreover, the preoperative inflammatory status can be leveraged for timely interventions to reverse the immunosuppressive status of cancer patients and enhance anti-tumour immunity of glioma.


Eligibility criteria:
inclusion criteria: * glioma grading and classification histologically verified in a resection or biopsy specimen according to 2016 who criteria; * age \> 18 years; * primary malignant glioma; * the duration of follow-up \> 3 months; * available data of lymphocyte subsets, cytokines, immune proteins and immune complements measured at the patient's first hospitalization. exculsion criteria: * current infectious disease, hyperpyrexia, hematological disease, diabetes mellitus, serious heart disease, hypertension, metabolic syndrome, severe renal or hepatic dysfunction, other cancer, autoimmune disease, inflammatory disease, or medication usage related to an inflammatory condition; * prior cancer-specific pretreatment, such as chemotherapy or radiotherapy;
aspirin resistance in coronary artery disease

Conditions: Coronary Artery Disease

Summary: the purpose of this study is to evaluate possible mechanisms of aspirin resistance at a molecular level in aspirin-treated patients with coronary artery disease. we hypothesize that certain patient characteristics associate with aspirin resistance. in addition, we will compare the effects of enteric-coated aspirin and chewable aspirin.

aspirin is commonly used for its antithrombotic effects in patients at risk for cardiovascular events. its primary mechanism of action is the irreversible acetylation of platelet cyclooxygenase-1, thereby inhibiting platelet production of thromboxane a2, a potent vasoconstrictor and activator of platelets. thromboxane a2, the major product of cyclooxygenase cytochrome oxidase (cox-1) in platelets, induces platelet aggregation. thromboxane b2 is an inactive metabolite/product of thromboxane a2. this primary outcome measures the extent of inhibition of platelet cox-1 by measuring the amount of the metabolite thromboxane b2 in serum. previous studies have demonstrated that many patients have recurrent events despite treatment with aspirin, which has been termed "aspirin resistance" or "aspirin nonresponse." this study addresses some of the possible mechanisms for aspirin nonresponse; specifically, we will test the hypothesis that aspirin nonresponse results from states that produce high peroxide concentrations ("oxidative stress") in platelets. in addition, we will evaluate the effect of enteric coating on the pharmacologic efficacy of aspirin in patients with coronary artery disease.

Eligibility criteria:
inclusion criteria: * on aspirin 81-325mg daily at time of enrollment * documented stable coronary artery disease or \> 6 months after coronary artery bypass grafting or interventional cardiac procedure * written informed consent exclusion criteria: * pre-menopausal female * renal disease (creatinine \>= 2 mg/dl) * anemia (hematocrit \< 30%) * thrombocytopenia (platelet count \< 135,000/ul) * use of nsaids or coxibs within the previous 2 weeks * concurrent use of other anti-platelet agents * uncontrolled hypertension (systolic bp \> 180 mmhg) * decompensated congestive heart failure * recent coronary syndrome (\< 6 months) * history of significant gi bleeding

Keywords: aspirin aspirin resistance aspirin nonresponse cyclooxygenase thromboxane oxidative stress
a study of the effectiveness of cognitive adaptation training in early intervention for psychosis

Conditions: Psychosis

Summary: the proposed study will involve a randomized trial of cognitive adaptation training (cat) for early intervention as compared against an active control in which action based cognitive remediation (abcr) will be applied.

the proposed project will expand knowledge of the role of compensatory and restorative cognitive interventions for early intervention population individuals with schizophrenia. the investigators will conduct a two arm randomized trial comparing the impacts of cat and action based cognitive remediation (abcr) for individuals with schizophrenia who are under the age of 30. the model would mirror the investigators' preliminary work at camh (kidd et al., 2014) in which there will be 4 months of specialist-delivered treatment followed by 5 months of maintenance by case managers with pre, 4 month, and 9 month evaluations conducted. this study will be among the most rigorous examinations of such interventions to date, would be among the first to examine integrative approaches, and would make a substantial contribution to the early intervention literature. the questions for the purposes of this project are: 1. is cat effective among individuals with schizophrenia under the age of 30? and 2. does integrating cognitive remediation with cat enhance outcomes as compared with cat alone?

Eligibility criteria:
inclusion criteria: * participants must be camh clients, have an assigned caseworker, be between the ages of 16-34 and have a psychosis such as schizophrenia or schizoaffective disorder. exclusion criteria: * not currently experiencing high level of paranoia.

Keywords: psychosis psychosis nos schizophrenia schizoaffective disorder early intervention
blood pressure variability and the prognosis of ischemic stroke with intracranial artery stenosis

Conditions: Blood Pressure Variability; Intracranial Artery Stenosis

Summary: correlation study about blood pressure variability and the prognosis of ischemic stroke with intracranial artery stenosis

extracranial atherosclerotic stenosis is the main reason for the european and american white ischemic stroke and transient ischemic attack,while atherosclerotic intracranial arterial stenosis is an important reason for asian patients with stroke ,accounting for the 33% to 51% of a etiology ratio.the latest research suggests that varying degrees of blood pressure variability can affect the risk of stroke.this study observe the relationship between blood pressure variability and prognosis of ischemic stroke patients with intracranial arterial stenosis,with cranial magnetic resonance imaging (mri + dwi),magnetic resonance angiography and trans-cranial doppler(tcd) .

Eligibility criteria:
inclusion criteria: * age : ≥ 18 years of age , ≤ 75 years old * with intracranial artery stenosis in ischemic stroke * the diagnosis of ischemic cerebrovascular disease are in line with the diagnostic criteria developed by the chinese medical association fourth national cerebrovascular disease conference * the patient admitted to hospital receive at least one examination like cranial mri + dwi, mra and tcd examination, clearly associated with intracranial arterial stenosis * mrs score ≤ 3 points exclusion criteria: * vascular , cardiac , and unknown causes or other reasons lead to ischemic stroke * associated with significant emotional disorders, cognitive impairment or other mental disorders can not be partners * severe occlusion of unilateral intracranial arteries ( over 90 % ) or bilateral stenosis more than 70% * with extracranial artery stenosis, especially carotid and vertebral artery stenosis . * patients with extracranial artery stenosis or patients previously done neck or intracranial artery balloon dilation , stent forming surgery or carotid endarterectomy * incomplete clinical data collection in patients
chronic pain and brain activity in spinal cord injury

Conditions: Spinal Cord Injury

Summary: this study compares five different procedures to see how they affect pain and brain activity. the procedures include neurofeedback, self-hypnosis training, meditation, and two different levels of transcranial direct current stimulation (tdcs). subjects will be compensated for their time.

during the first study visit, subjects will receive a physical exam and an electroencephalogram (eeg), which measures brain activity. research staff will put a cap on your head that has sensors which measure your brain activity. there is no risk of electrical shock. in addition to the sensors in the cap, two clips will be put on your ears. eeg activity will be collected for 20 minutes: you will have your eyes open for ten minutes, and then have your eyes closed for ten minutes. additional study visits will follow where we will perform five different procedures (neurofeedback, self-hypnosis, two levels of transcranial direct current stimulation, and meditation). all subjects will receive all five procedures and each procedure will be conducted for 20 minutes. self-hypnosis training: you will be given verbal suggestions from an audio recording (via headphones) for relaxation and changes in the way you think about pain. meditation: you will be asked to focus on a single word ("one") for the entire session. neurofeedback training: during this procedure, three sensors will be placed on your scalp, and one on each earlobe. a small amount of electrode paste will be used when placing the sensor on your scalp. there is no risk of electrical shock. you will be able to see images on a computer screen that correspond to your brain waves. you will learn how to change your brainwaves by changing the images on the computer. electric stimulation (two different levels): this procedure consists of direct stimulation of the brain by a weak electrical current. the two procedure sessions will differ in the characteristics of the stimulation. two electrodes will be placed on your scalp and secured by a rubber strap. the tdcs procedure is considered experimental and is not currently approved by the fda but has been studied previously, at the same level of current, in spinal cord injury. before and after each procedure we will complete a 10 minutes eeg assessment similar to what is described above. the final procedure session will end with a 20 minute assessment to determine how responsive you are to hypnosis. each procedure visits may last up to three hours. there will be a total of 6 study visits over approximately 2 months.

Eligibility criteria:
inclusion criteria: * diagnosed with spinal cord injury * 18 years of age or older * daily pain * at least 12 months since injury * read speak and understand english exclusion criteria: * history of seizure disorder or non-normative brain activity * presence of traumatic brain injury or significant skull defects * exhibit moderate to severe cognitive impairment

Keywords: spinal cord injury chronic pain
a study of lymph node metastatic pattern based incorporating tumor location, ggo components and size for non-small cell lung cancer

Conditions: Lung Cancer Non Small Cell

Summary: the goal of this observational study is to learn about in invasive non-small cell lung cancer patients who underwent pulmonary resection with systematic lymph node dissection from april 2008 to july 2022 . the main question it aims to answer are: determine the situation of zero risk mediastinal lymph metastases and the different lymph node metastatic patterns of tumors with different characteristics. participants will provide personal information to analyze. and there is not a comparison group.


Eligibility criteria:
inclusion criteria: * invasive non-small cell lung cancer patients in fuscc who underwent pulmonary resection with systematic lymph node dissection from april 2008 to july 2022 exclusion criteria: * none
carnitine supplementation and skeletal muscle function

Conditions: Sarcopenia

Summary: research project objectives the primary aim of the current research project is to use carnitine supplementation as the anti-inflammatory intervention for exploring the relationship between inflammation and associated with aging reduction of skeletal muscle mass. hypothesis the carnitine supplementation modulates the blood cytokines concentration. anti-inflammatory intervention delay the reduction of skeletal muscle mass associated with aging

volunteers over 65 years old (n=40) are supplemented either with carnitine or placebo for 24 weeks. before the start, in the mid-point, and after finishing the supplementation the following primary outputs variables are performed: body composition analysis (inbody720), maximal isokinetic knee extensor peak torque (biodex system 4 pro), blood cytokines and carnitine concentration, blood lipid profile.

Eligibility criteria:
inclusion criteria: * subjects with no history of gastrointestinal disorders, cardiovascular disease or hypertension. exclusion criteria: * subjects having any illnesses and a history of gastrointestinal disorder, cardiovascular disease, hypertension, liver and renal disease, diabetes, cancer, alcoholism or other metabolic diseases.

Keywords: carnitine
post-discharge nutrition and resistance training in surgical patients

Conditions: Malnutrition; Surgery

Summary: randomized intervention by nutritional supplements and training in postoperative patients after discharge

surgery combined with malnutrition is associated with loss of muscle mass and leads to serious consequences for the surgical patient. a majority of surgical patients continue to lose weight after discharge. nutritional risk screening has not been fully implemented at landssjúkrahúsið - the national hospital of the faroe islands and therefore the prevalence of patients at nutritional risk is unknown. the aim of this study is to examine whether an intervention with independent nutritional supplements or an intervention combining nutritional supplements and resistance training is more effective in preventing loss of muscle mass than standard care in surgical patients following discharge. secondary outcomes are changes in body weight, quality of life, muscle strength and activities of daily living. furthermore, we want to screen hospitalized surgical patients for nutritional risk in order to get an estimate of the prevalence of nutritional risk.

Eligibility criteria:
inclusion criteria: * admitted to the surgical departments at landssjúkrahúsið - national hospital of faroe islands * aged 18 years or above * one or more of the following surgical procedures: knee alloplasty, hip alloplasty, collum femoris fracture, back fracture, abdominal surgery, mamma surgery and other comprehensive surgery * at nutritional risk according to screening exclusion criteria: * minimally invasive surgery/laparoscopic surgery * severely reduced kidney function (p-creatinin\>250 mikromol/l) or dialysis * terminal illness * inability to cooperate in tests or exercises due to cognitive function or dementia * admitted to intensive care unit * inability to speak or understand faroese, danish or english * consent according to national regulations not obtainable
mental status and quality of life of post-covid-19 patients

Conditions: Covid19

Summary: the current sars-cov-2 virus pandemic has already affected the lives of every person on earth. most of the information given in the media on a daily basis focuses on the pandemic aspects. fear of getting sick arises in the population, and once infection occurs, numerous concerns arise over the course of the disease. for some patients, hospitalization and subsequent rehabilitation is needed due to complications from the disease. besides the aspect of treating patients physically from the disease, the psychological aspects that often accompany patients during and after the disease are not addressed. depressive and anxiety symptoms can follow patients for many years and can affect their quality of life. thus, the purpose of this project is to assess the mental status of patients prior to the inpatient rehabilitation program

patients with covid-19 or post-covid-19 will have a need for rehabilitation during and directly after hospitalization. data on safety and efficacy are lacking, as the number of covid-19 survivors has increased rapidly. the convergence of opinion on recommendations and evidence process was used to make interim recommendations for the in-hospital rehabilitation and post-hospital phase in patients with covid-19 and post-covid-19 patients, respectively. the international task force (its) was established, including the european respiratory society (ers) and key opinion leaders from the american thoracic society (ats), as well as key opinion leaders in the field of lung rehabilitation. in its report, the its identified recommendations for the rehabilitation of patients with covid-19 and post-covid-19 patients. majority of the experts recommended strongly (71%) or conditionally (24%) for covid-19 survivors with symptoms of psychological distress at 6-8 weeks after discharge from the hospital receiving a formal psychological assessment. therefore, this project aims to evaluate the mental status and quality of life of patients admitted to the rehabilitation unit, after covid-19 hospitalization. in our project, we intend to answer the following questions: * what is the severity of depressive symptoms in individuals who have suffered covid-19 ? * what is the severity of anxiety symptoms in individuals who have suffered covid-19 ? * what is the level of perceived stress in individuals who have suffered covid-19 ? * what is the quality of life of people in individuals who have suffered covid-19 ?

Eligibility criteria:
inclusion criteria: * previously hospitalized for sars-cov-2 infection; * pulmonary rehabilitation conducted in ward settings exclusion criteria: * inability to self-complete the research questionnaires; * presence of the following issues at the time of the examination or in the medical data: disturbances of consciousness, psychotic symptoms or other serious psychiatric disorders * initiation of psychiatric treatment during the research project; * patient's refusal at any stage of the research project.

Keywords: quality of life hads rehabilitation anxiety
paraneoplastic syndrome in hepatocellular carcinoma patients

Conditions: Hepatocellular Carcinoma Patients

Summary: hepatocellular carcinoma (hcc) is the sixth most common cancer in the world with rising incidence. globally, there has been substantial variation in prevalence of risk factors for hcc over years, like control of viral hepatitis in developing countries but growing epidemic of fatty liver disease in developed world. changing epidemiology of hcc is related to trends in these risk factors, paraneoplastic syndromes (pns) are defined as systemic, metabolic, or other distant consequences of malignancy resulting, either directly or indirectly, from production by the neoplasm of substances that gain access to the blood stream, thereby exerting their effects on distant organs or tissues there is four major hcc-associated paraneoplastic syndromes among cirrhotic patients,i.e.hypercholesterolemia,hypoglycemia,hypercalcemia,and erythrocytosis .


Eligibility criteria:
inclusion criteria: * - cirrhotic patients with hcc. * hcc will be diagnosed based on alpha -feto protein (afp) and dynamic imaging. exclusion criteria: * - patient known to have primary parathyroid disease, patients with bone metastasis or excessive use of antacids. * patients with secondary polycythemia (as chronic hypoxia) and patients with polycythemia rubra vera. * patients with acute infections or git bleeding. * patients with preexisting dyslipidemia. * patients with significant cholestasis.
a clinical trial on hb-vac activated-dcs combined with peg-ifn or nas in chb

Conditions: Chronic Hepatitis B

Summary: the purpose of this study is to investigate whether hb-vac activated-dcs combined with peg-ifn or nas has more efficacy than peg-ifn or nas alone in the treatment of chronic hepatitis b patients

the 450 patients meeting the entry criteria are divided into 6 groups, the clinical trial procedure is divided into 3 parts, according to the following steps: part1 (0-12w): 1. the research objects will be grouped according to the principle of a multicenter, randomized, open, parallel controlled clinical trial, 300 cases of cell therapy groups (100 cases with peg-ifn treatment, ldt treatment for 100 cases, etv treatment for 100 cases), 150 cases of control groups (peg-ifn therapy in 50 cases, ldt therapy for 50 cases, etv treatment for 50 cases). part2 (12-36w): 2. cell therapy groups: enter the hbsag sensitized dendritic cells activated t cells (hbsag pulse dcs-t, hpdcs-t) immune therapy combined with interferon (ifn) or nucleoside analogues treatment (nas), infusion of hpdc-t every 2 weeks for 1 time, total 12 times. 3. control groups: antiviral therapy used only (ifn or nas). part3 (36-72w): 4. the observation stage: discontinuation of interferon in the treatment of 48 weeks; nas cases will continue on treatment with nas. hpdcs-t produced procedure: the first step: 1-7 days monocytes will be isolated from peripheral blood of patients. the monocytes obtained will be then incubated in fresh serum-free aim-v medium (gibco) containing 800u/ml of gm-csf and 400u/ml of il-4 (peprotech) for 5 days. after 5 days of culture in vitro, the dcs induced will be cultured with a commercially available hepatitis b vaccine containing 10 ug of hbsag (gsk) for 2 days. the second step: 8-14 days the hepatitis b vaccine sensitized dcs (hpdcs) (from the first step) will be sub-cultured with patient's own pbmcs for 7 days: hbsag can be efficiently presented to pbmcs by dcs, with producing hbv specific ctls and htls (hpdcs-t). the third step: 15 days the pbmcs (the second step) containing enough hpdcs-t will be transfused back into the patient.

Eligibility criteria:
inclusion criteria: serum hepatitis b surface antigen(hbsag) positive for at least 6 months; hbv dna loads≥ 104iu/ml(roche cobas); containing the ifn treatment: 2uln ≤ alt ≤ 10uln and tbil ≤ 2uln; containing the etv/ldt treatment: 2uln ≤ alt and tbil ≤ 5uln; all patients have not received antiviral treatment or immunotherapy for the last 6 months. exclusion criteria: superinfection or co-infection with hepatitis a, c, d, e, cytomegalovirus and hiv, or epstein-barr virus; other liver diseases such as alcoholic liver disease, drug-induced hepatitis, wilson disease and autoimmune hepatitis; ascites or gastrointestinal bleeding or peptic ulcer or esophageal varix by electronic gastroscope examination; liver cirrhosis; severe bacterial or fungal infections; a history of diabetes or cardiac disease or hypertension or nephrosis; pregnant women.

Keywords: chb antiviral dentritic cells immune therapy
to investigate the effect of montelukast on behavior problems in children with asthma

Conditions: Asthma, Behavior Problem, Montelukast

Summary: the purpose of the study to investigate whether montelukast lead to behavior problems in children with asthma.


Eligibility criteria:
inclusion criteria: * to have asthmatic children aged 18-60 months * to have that receive prophylactic treatment for asthma * healthy children will be enrolled among those being brought for routine controls exclusion criteria: * children with other chronic disease * children with chronic drug use (except for the treatment of asthma)